Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Chugai Pharmaceutical
Age
20–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
Patients who contracted RA at least 6 months prior
You may not be if
Patients with Class IV Steinbrocker functional impairment at enrollment.
Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug
